The rise of antibiotic resistance, together with collateral damage to the human microbiota as a result of antibiotic use, means that new antimicrobials need to be developed. Here, Cotter, Ross and Hill discuss the potential of bacteriocins, which are active against a range of bacteria, have low toxicity towards the host, are easily modifiable and can even be producedin situ.
- Paul D. Cotter
- R. Paul Ross
- Colin Hill